

CITATION REPORT

List of articles citing

On the receiving end--patient perception of the side-effects of cancer chemotherapy

DOI: 10.1016/0277-5379(83)90418-2
European Journal of Cancer & Clinical Oncology, 1983,
19, 203-8.

Source: <https://exaly.com/paper-pdf/16343466/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
698	On the receiving end--II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1983 , 19, 1633-7		126
697	Control of cancer chemotherapy-induced nausea and vomiting. 1984 , 54, 2642-8		22
696	Advances in anti-emetic therapy. 1984 , 11, 237-56		54
695	Current status of chemotherapy of breast cancer. 1984 , 28, 93-8		2
694	Doing the best for the cancer patient. 1985 , 1, 35-8		14
693	Chemotherapy of advanced ovarian adenocarcinoma: a randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin. 1986 , 23, 1-13		28
692	Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. 1986 , 293, 1334-7		36
691	Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. 1986 , 17, 285-8		35
690	Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. 1987 , 295, 250		17
689	The management of nausea and vomiting in clinical oncology. 1987 , 293, 34-44		72
688	A method of calculating the value of palliative care of cancer patients. 1987 , 57, 393-7		7
687	Chemotherapy: An Overview of Nausea and Vomiting in the Cancer Patient: Etiology and Management of Serious Complications of Chemotherapy. 1987 , 35, 179-182		
686	Examination of the correlation of serum metoclopramide levels with antiemetic efficacy in patients receiving cisplatin. 1987 , 20, 332-6		5
685	Mechanisms and management of chemotherapy-induced nausea and vomiting. 1987 , 1, 50-7		13
684	Who should measure quality of life, the doctor or the patient?. 1988 , 57, 109-12		735
683	Review article : Emesis in the patient with advanced cancer. 1988 , 2, 89-100		11
682	Comparison of starting antiemetic treatment 24 hours before or concurrently with cytotoxic chemotherapy. 1989 , 298, 430-1		8

681	Ratings of cancer chemotherapy toxicity by oncologists, nurses, and pharmacists. 1989 , 4, 7-13	10
680	Antiemetic superiority of lorazepam over oxazepam and methylprednisolone as premedicants for patients receiving cisplatin-containing chemotherapy. 1989 , 64, 1595-9	17
679	Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. 1989 , 3, 216-21	6
678	Current status of clinical trials of therapeutic modalities for malignant melanoma in Australia. 1989 , 2, 370-1	2
677	Treatment decisions in advanced ovarian cancer. 1989 , 60, 155-6	6
676	Distress associated with radiotherapy for malignant disease: a quantitative analysis based on patients perceptions. 1989 , 60, 370-4	29
675	The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. 1989 , 60, 759-63	16
674	A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 1457-61	15
673	Managing the side effects of chemotherapy. 1989 , 5, 29-52	19
672	Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone. 1989 , 115, 156-60	26
671	On the receiving end--III. Measurement of quality of life during cancer chemotherapy. 1990 , 1, 213-7	65
670	Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. 1990 , 61, 56-60	41
669	Factors of importance when evaluating quality of life in clinical trials. 1990 , 11, 169-79	75
668	Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. 1990 , 66, 1101-5	25
667	Making chemotherapy easier. 1990 , 322, 846-8	26
666	A study of the relative frequency and importance of gastrointestinal symptoms, and weakness in patients with far advanced cancer: student paper. 1990 , 4, 37-43	60
665	Introduction. 1990 , 6, 1-2	1
664	Psychologic aspects of the treatment of emesis in cancer nursing. 1990 , 6, 6-9	5

663	Quality of life after treatment for testicular cancer--the patient's view. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 291-4	22
662	Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 1038-42	37
661	Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. 1991 , 338, 483-7	195
660	Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. 1991 , 338, 487-90	201
659	Controlling emesis related to cancer therapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 356-61	24
658	How should nausea be assessed in patients receiving chemotherapy?. 1991 , 18, 85-93	6
657	The current role of anti-emetic drugs in oncology: a recent revolution in patient symptom control. 1991 , 18, 95-135	44
656	Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. 1991 , 42, 805-24	70
655	On the receiving end. IV: Validation of quality of life indicators. 1991 , 2, 597-603	65
654	High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting. 1991 , 2, 223-7	5
653	5-Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis. 1991 , 117, 85-7	6
652	Recent clinical experience with dronabinol. 1991 , 40, 695-700	181
651	Theories of self-care: their relevance to chemotherapy-induced nausea and vomiting. 1991 , 16, 671-6	4
650	Advances in the management of cytotoxic drug-induced nausea and vomiting. 1991 , 16, 411-21	6
649	Controlling cancer chemotherapy-induced emesis. An update. 1991 , 13, 189-97	6
648	Clinical pharmacology and therapeutics. 1991 , 67, 1042-54	4
647	Intraosseous infusions: an important but forgotten method of vascular access. 1991 , 9, 521-8	5
646	Emesis Control in Hematological-Oncology. 1992 , 7, 83-89	

645	Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. 1992 , 31, 573-5	19
644	Advances in the control of chemotherapy-induced emesis. 1992 , 3 Suppl 3, 47-50	9
643	Anticipatory nausea and vomiting among cancer patients: A Review. 1992 , 6, 97-106	14
642	Psychosocial issues in the treatment of patients with lung cancer. 1992 , 8, 1-20	13
641	Are granisetron and ondansetron equivalent in the clinic?. 1992 , 28A Suppl 1, S32-5	10
640	Adverse effects of cancer chemotherapy. An overview of techniques for avoidance/minimisation. 1992 , 7, 316-22	2
639	Ondansetron: a pharmaco-economic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. 1992 , 2, 285-304	21
638	Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. 1992 , 28, 450-7	61
637	A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group. 1992 , 28A Suppl 1, S12-6	24
636	Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group. 1992 , 28A Suppl 1, S21-8	13
635	Oral granisetron--simple and effective: a preliminary report. The Granisetron Study Group. 1992 , 28A Suppl 1, S28-32	16
634	Treatment related psychological distress during adjuvant chemotherapy as a conditioned response. 1992 , 3, 393-8	17
633	Application of Quality of Life Measures in Health Care Delivery. 1992 , 8, 18-21	3
632	The distinction between affect and cognition in the quality of life of cancer patients--sensitivity and stability. 1992 , 1, 315-22	38
631	Quality of life consequences of chemotherapy-induced emesis. 1992 , 1, 331-40	211
630	Anticipatory nausea and emesis, and psychological morbidity: assessment of prevalence among out-patients on mild to moderate chemotherapy regimens. 1992 , 66, 862-6	29
629	The management of nausea and vomiting induced by chemotherapy and radiotherapy: a comprehensive guide for nurses. 1992 , 1, 23-26	
628	NEWS. 1992 , 1, 4-6	

627	Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease. <i>Journal of Pharmaceutical Sciences</i> , 1993 , 82, 1281-4	3.9	15
626	Patient assessment of a combined medical and nursing preparation to cytotoxic chemotherapy. <i>Supportive Care in Cancer</i> , 1993 , 1, 209-13	3.9	1
625	Methodological issues in antiemetic studies. 1993 , 11, 243-53		23
624	Measuring quality of life. 1993 , 2, 77-81		10
623	The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. 1993 , 119, 555-9		15
622	Granisetron, ein neues und potentes Antiemetikum zur Behandlung der zytostatikainduzierten Emesis. 1993 , 254, 1068-1070		
621	Control of chemotherapy-induced emesis. 1993 , 329, 1790-6		174
620	A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimen. 1993 , 29A, 309-15		5
619	5-HT ₃ receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. 1993 , 29A, 1669-72		86
618	Ondansetron: costs and resource utilisation in a US teaching hospital setting. 1993 , 3, 471-81		10
617	Prevalence of anticipatory nausea and other side-effects in cancer patients receiving chemotherapy. 1993 , 29A, 866-70		30
616	The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. 1993 , 29A, 303-6		40
615	Clinical studies with granisetron, a new 5-HT ₃ receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group. 1993 , 29A Suppl 1, S22-9		13
614	Chemotherapy made easier. 1993 , 23, 387-92		3
613	The budgetary impact of 5-HT ₃ receptor antagonists in the management of chemotherapy-induced emesis. 1992 , 29A, 51-6		116
612	Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. 1993 , 4 Suppl 3, 39-42		12
611	Tropisetron and the 5-HT ₃ antiemetics in perspective. 1993 , 4, S1		1
610	The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group. 1993 , 68, 176-80		36

609	Quality of Life Issues in Lung Cancer. 1993 , 103, 51S-55S		2
608	Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. 1993 , 32, 413-5		8
607	Control of Nausea and Vomiting by Granisetron in Ovarian Cancer Patients Treated with Different Cisplatin-Based Regimens. 1994 , 80, 344-347		0
606	Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. 1994 , 41, 1117-9		28
605	Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience. <i>Supportive Care in Cancer</i> , 1994 , 2, 393-9	3.9	6
604	Costs and benefits of antiemetic therapy. <i>Supportive Care in Cancer</i> , 1994 , 2, 304-6	3.9	2
603	Antiemetics in cancer chemotherapy: historical perspective and current state of the art. <i>Supportive Care in Cancer</i> , 1994 , 2, 150-60	3.9	7
602	Choices in oncology: factors that influence patients' treatment preference. 1994 , 3, 175-82		38
601	A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT ₃ receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. 1994 , 73, 445-54		33
600	Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group. 1994 , 69, 967-71		55
599	A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin. 1994 , 85, 1151-8		20
598	Cancer therapy-induced emesis: the nurse's perspective. 1994 , 3, 18-25		3
597	Patient choice in management. 1994 , 3, 87-90		
596	Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study. 1994 , 38, 282-4		5
595	[Antiemetic treatment and chemotherapy: general review]. 1994 , 15, 752-69		1
594	A return to "normal eating" after curative treatment for oral cancer. What are the long-term prospects?. 1994 , 30B, 387-92		37
593	Efficacy and safety of antiemetics. 1994 , 20, 379-92		7
592	Comparison of Ondansetron with Metoclopramide in the Control of Emesis Induced by Moderately Emetogenic Chemotherapy Used for Lymphoma and Leukaemia Patients. 1994 , 8, 104-109		

591	Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naïve and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). 1994 , 5, 253-8		33
590	Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. 1994 , 5, 579-4		46
589	Granisetron: the second serotonin-receptor antagonist. 1995 , 29, 1240-51		16
588	Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. 1995 , 29, 16-21		29
587	Fatigue in cancer patients: a review of the literature. 1995 , 4, 20-32		154
586	Acute leukaemia and malignant lymphoma patients' experiences of disease, treatment and nursing care during the active treatment phase: an explorative study. 1995 , 4, 133-42		31
585	Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytrel), and tropisetron (Navoban). 1995 , 76, 343-57		82
584	Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. 1995 , 76, 2330-7		12
583	Variation in the use of ondansetron as an antiemetic drug in children treated with chemotherapy. 1995 , 25, 33-7		6
582	A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. <i>Supportive Care in Cancer</i> , 1995 , 3, 301-6	3-9	14
581	Antiemetic Therapy in the Outpatient Oncology Setting. 1995 , 8, 269-279		
580	Development of a Home Chemotherapy Program for Pediatric Oncology Patients. 1995 , 8, 297-302		2
579	Inhibitory effects of combined administration of 5-FU and Krestin on liver cancer KDH-8 in WKA/H rats. 1995 , 8, 1-5		1
578	Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. 1995 , 73, 243-5		33
577	Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. 1995 , 31A, 1955-9		97
576	Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. 1995 , 17, 1091-8		11
575	Efficacy and tolerability of granisetron with betamethasone, an antiemetic combination, in gynecologic cancer patients receiving cisplatin. 1995 , 56, 1059-1065		0
574	Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. 1995 , 98, 224-31		182

573	Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. 1995 , 35, 278-82	38
572	Comparative adverse effect profiles of platinum drugs. 1995 , 13, 228-44	226
571	Nausea, vomiting, and retching: the management of the symptom experience. 1995 , 11, 256-65	14
570	Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. 1996 , 32A, 1523-9	32
569	Effect of cisplatin on dopamine release from PC12 cells. 1996 , 59, 1793-801	8
568	Efficacy and safety of ondansetron in pediatric patients undergoing bone marrow transplantation. 1996 , 18, 466-76	16
567	Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting. 1996 , 9, 357-74	5
566	A Pilot Study of Cognitive Behavioral Therapy and Social Support Group Interventions with Newly Diagnosed Cancer Patients. 1996 , 14, 65-83	43
565	Radiotherapy for cancer. Quality of life. 1996 , 35 Suppl 7, 141-8	6
564	Chemotherapy-Induced Nausea and Vomiting: Rationale for Cost-Effective Management. 1996 , 3, 242-249	1
563	Ethical issues regarding study designs used in serotonin-antagonist drug development. 1996 , 30, 1182-4	3
562	Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. 1996 , 7, 277-82	21
561	A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. 1996 , 7, 945-52	55
560	Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. 1996 , 35, 159-63	10
559	Cancer-related issues for women. 1996 , NS36, 655-60	
558	A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. 1996 , 7, 505-10	6
557	On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. 1996 , 7, 189-95	290
556	What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. 1996 , 73, 222-7	62

555	A quantitative approach to the distress caused by symptoms in patients treated with radical radiotherapy. 1996 , 74, 640-7		58
554	Group cognitive behavioural therapy: an intervention for cancer patients. 1996 , 2, 131-137		6
553	New perspectives in antiemetic treatment. <i>Supportive Care in Cancer</i> , 1996 , 4, 416-9	3.9	17
552	Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. <i>Supportive Care in Cancer</i> , 1996 , 4, 435-9	3.9	44
551	Quality of life in patients with ovarian cancer: current state of research. <i>Supportive Care in Cancer</i> , 1996 , 4, 169-79	3.9	46
550	A controlled, dose-comparison study of granisetron for nausea and vomiting induced by cancer chemotherapy in children. 1996 , 1, 57-60		3
549	Issues in antiemetic therapy. 1996 , 77, 823-6		3
548	A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. 1996 , 78, 144-51		19
547	High-performance liquid chromatographic determination of granisetron in human plasma. 1996 , 675, 99-105		19
546	Group cognitive behavioural therapy interventions with cancer patients: a review of the literature. 1996 , 5, 143-6		21
545	Measuring quality of life in oncology: is it worthwhile? II. Experiences from the treatment of cancer. 1996 , 5, 168-75		17
544	Advances in supportive care. 1996 , 5, 1-7		13
543	Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. 1996 , 74, 323-6		12
542	5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis. 1996 , 74, 1137-40		6
541	Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study. 1997 , 36, 229-30		4
540	Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. 1997 , 8, 825-35		56
539	Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. 1997 , 76, 1055-61		273
538	Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care. 1997 , 76, 1640-5		71

537	Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413. 1997 , 76, 90-2		33
536	Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. 1997 , 15, 297-303		15
535	Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. 1997 , 33, 297-300		38
534	A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy. 1997 , 33, 1605-10		14
533	Survey of the incidence and severity of side-effects reported by patients receiving six cycles of FEC chemotherapy. 1997 , 1, 61-73		16
532	Cancer support groups--are they effective?. 1997 , 6, 11-7		25
531	[Effectiveness and cost of 5-HT3-antagonists in acute chemotherapy-induced emesis. Health-economic analysis based on current meta-analytic data]. 1997 , 92, 747-52		2
530	Changes in self-concept and body image during alopecia induced cancer chemotherapy. <i>Supportive Care in Cancer</i> , 1997 , 5, 139-43	3.9	126
529	Psychosocial problems in cancer care: a brief review of common problems. 1997 , 4, 323-31		21
528	The hidden experience of radiotherapy to the head and neck: a qualitative study of patients after completion of treatment. 1998 , 28, 840-8		63
527	Patient satisfaction with cancer chemotherapy nursing: a review of the literature. 1998 , 35, 1-12		41
526	A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. 1998 , 83, 1022-1032		16
525	[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]. 1998 , 93 Suppl 1, 3-17		5
524	Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. 1998 , 7, 371-9		30
523	[Treatment of chemotherapy induced emesis in children]. 1998 , 5, 661-8		1
522	Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy. 1998 , 34, 196-8		10
521	Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review. 1998 , 34, 1836-44		46
520	Nurses' assessments of symptom occurrence and symptom distress in chemotherapy patients. 1998 , 2, 14-26		18

519	Study of patient satisfaction with chemotherapy nursing care. 1998 , 2, 142-153	20
518	Options in the treatment of chemotherapy-induced emesis. 1998 , 6, 276-81	21
517	Quality-of-life assessment in health care research and practice. 1998 , 21, 141-56	13
516	Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. 1998 , 77, 1487-91	35
515	Chemotherapy-Induced Nausea and Vomiting. 1998 , 6, 23-50	
514	Palliative chemotherapy. 1998 , 15, 93-103	12
513	Recent progress in understanding cancer-related fatigue. 1998 , 4, 192-198	7
512	Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. 1998 , 9, 661-6	65
511	Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice. <i>Oncologist</i> , 1999 , 4, 191-196	5:7 107
510	Quality of life in advanced ovarian cancer: identifying specific concerns. 1999 , 2, 397-402	25
509	Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. 1999 , 32, 105-12	13
508	5-HT ₃ antiemetic therapy for patients with breast cancer. 1999 , 57, 207-14	14
507	Intravenous itasetron: establishing the effective dose range for the prophylactic control of acute emesis in cancer patients undergoing high-dose cisplatin chemotherapy. 1999 , 11, 99-104	
506	Symptoms 2 weeks, 3 months and 12 months after treatment of early breast cancer: the patients' perspectives. 1999 , 8, 273-7	4
505	Perception of chemotherapy side effects cancer versus noncancer patients. 1999 , 7, 59-65	123
504	New oral chemotherapeutic agents for lung cancer. 1999 , 58 Suppl 3, 57-69	10
503	Development and evaluation of a questionnaire to assess patient satisfaction with chemotherapy nursing care. 1999 , 3, 126-140	14
502	Guidelines for anti-emetic therapy: acute emesis. 1999 , 35, 361-70	25

501	Pharmacokinetics, Tolerability and Efficacy of Bolus-Dose vs Continuous-Infusion Granisetron in the Prevention of Vomiting in Patients Undergoing Haematopoietic Stem-Cell Transplantation. 1999 , 17, 155-165	1
500	Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. 1999 , 21, 274-83	10
499	Body image dimensions and cancer: a heuristic cognitive behavioural model. 2000 , 9, 183-92	172
498	A pilot study of the use of progressive muscle relaxation training in the management of post-chemotherapy nausea and vomiting. 2000 , 9, 230-4	37
497	Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. 2000 , 25, 1279-83	18
496	Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. 2000 , 20, 113-21	112
495	Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). 2000 , 9, 151-9	30
494	A Randomized Open-Label Parallel-Group Study Comparing Ondansetron with Ondansetron plus Dexamethasone in Patients with Metastatic Breast Cancer Receiving High-Dose Epirubicin. A Hellenic Cooperative Oncology Group Study. 2000 , 86, 37-41	8
493	Basic Bibliographies. 2000 , 35, 891-893	
492	Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy. 2000 , 34, 573-9	1
491	Advances in use of the 5-HT ₃ receptor antagonists. 2000 , 1, 207-23	36
490	Evaluating the efficacy of scalp cooling using the Penguin cold cap system to reduce alopecia in patients undergoing chemotherapy for breast cancer. 2000 , 4, 246-8	25
489	Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. 2000 , 36, 1522-35	17
488	What really bothers oncology patients. 2000 , 17, 439-40	
487	Comparative review of 5-HT ₃ receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. 2000 , 18, 163-73	143
486	Topical application of cyclosporin A induces rapid-remodeling of damaged anagen hair follicles produced in cyclophosphamide administered mice. 2001 , 27, 7-13	18
485	An evaluation of the quality of a chemotherapy administration service established by nurses in an oncology day care centre. 2001 , 5, 244-53	6
484	Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. 2001 , 2, 691-7	88

483	This CE is published through an unrestricted educational grant from Bristol-Myers Squibb: Prevention and Management of Chemotherapy-Induced Nausea and Vomiting, Part 1. 2001 , 36, 67-82	6
482	Palliative systemic antineoplastic therapy. 2001 , 399-420	
481	Understanding patient preferences for the treatment of lupus nephritis with adaptive conjoint analysis. 2001 , 39, 1203-16	62
480	Dimensions of fatigue during radiotherapy--an application of the Swedish Occupational Fatigue Inventory (SOFI) on cancer patients. 2001 , 40, 37-43	32
479	A stochastic model to analyse risk factors for emesis in multi-cycle chemotherapies. 2001 , 96, 221-246	1
478	Hair and cancer chemotherapy: consequences and nursing care--a literature study. 2001 , 10, 147-63	115
477	The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting. 2001 , 13, 422-6	4
476	Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. 2001 , 28, 1061-6	15
475	Are quality of life measures patient centred?. 2001 , 322, 1357-60	357
474	Pharmacologic insights into the future of trastuzumab. 2001 , 12 Suppl 1, S43-7	12
473	The measurement, causes and effective management of cancer-related fatigue. 2002 , 8, 120-8	49
472	Gender and anthropometrics of patients undergoing cisplatin-containing chemotherapy as determinants of acute emesis over repeat courses. 2002 , 8, 89-95	
471	Unwillingness of rheumatoid arthritis patients to risk adverse effects. 2002 , 41, 253-61	44
470	Clinical assessment of ramosetron HCl oral preparation in the treatment of nausea and vomiting induced by cisplatin: A multicenter, randomized, parallel-design, double-blind comparative study with ondansetron HCl. 2002 , 63, 636-648	3
469	New agents, new treatment, and antiemetic therapy. 2002 , 29, 119-24	18
468	Changing patient perceptions of the side effects of cancer chemotherapy. 2002 , 95, 155-63	320
467	Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. 2002 , 30, 119-24	11
466	Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. 2002 , 30, 593-7	36

465	Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. 2002 , 87, 118-28		58
464	The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?. <i>Supportive Care in Cancer</i> , 2004 , 12, 626-33	3.9	47
463	The effect of electroacupuncture as an adjunct on cyclophosphamide-induced emesis in ferrets. 2003 , 74, 691-9		26
462	Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. 2003 , 97, 2880-6		174
461	Measuring chemotherapy-induced nausea and emesis. 2003 , 98, 645-55		39
460	Are health states 'timeless'? A case study of an acute condition: post-chemotherapy nausea and vomiting. 2003 , 9, 69-82		12
459	Assessment of respondent acceptability of preference measures: discriminatory power of graphic positioning scale versus traditional scaling measures. 2003 , 6, 483-93		5
458	Hypnotherapy and cognitive-behaviour therapy in cancer care: the patients' view. 2003 , 12, 137-42		7
457	Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. 2003 , 88, 1823-7		21
456	Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. 2003 , 1, 46		79
455	Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. 2003 , 5, 597-613		32
454	Why do we need another antiemetic? Just ask. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4077-80	2.2	40
453	Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. <i>Oncologist</i> , 2003 , 8, 187-98	5.7	164
452	Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. 2003 , 4, 2297-303		39
451	Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. 2003 , 37, 1276-86		89
450	Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1373-8	2.2	63
449	Nurses' repeat measurement of chemotherapy symptoms: feasibility, resulting information, patient satisfaction. 2003 , 26, 468-75		16
448	Neural networks as effective techniques in clinical management of patients: some case studies. 2004 , 26, 169-183		5

447	Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. <i>Oncologist</i> , 2004 , 9 Suppl 6, 14-24	5.7	43
446	Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting. 2004 , 58, 201-6		12
445	Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. <i>Supportive Care in Cancer</i> , 2004 , 12, 543-9	3.9	93
444	Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT ₃ receptor antagonists in cancer patients. 2004 , 54, 185-90		19
443	Male sexuality after cancer treatment--needs for information and support: testicular cancer compared to malignant lymphoma. 2004 , 52, 143-50		61
442	Illusions in advanced cancer: the effect of belief systems and attitudes on quality of life. 2004 , 13, 26-36		24
441	Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. 2004 , 100, 2261-8		339
440	RiskBenefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. 2004 , 3, 231-248		19
439	Palonosetron. 2004 , 64, 1125-32; discussion 1133-4		39
438	[Effectiveness of anti-emetics for the prophylaxis of cisplatin-induced delayed emesis: a systematic review]. 2004 , 124, 1-11		8
437	Pharmacophore based synthesis of 3-chloroquinoxaline-2-carboxamides as serotonin ₃ (5-HT ₃) receptor antagonist. 2004 , 27, 1403-5		19
436	Patients' need for information about cancer therapy. 2004 , 31, 313-9		80
435	Update on anti-emetics for chemotherapy-induced emesis. 2005 , 35, 478-81		17
434	5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?. 2005 , 104, 1-18		26
433	Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. <i>Supportive Care in Cancer</i> , 2005 , 13, 26-31	3.9	16
432	Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. <i>Supportive Care in Cancer</i> , 2005 , 13, 219-27	3.9	225
431	Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. <i>Supportive Care in Cancer</i> , 2005 , 13, 375-80	3.9	13
430	ESMO 2004 Nausea e Vomito da Chemioterapia: Ottimizzazione del Trattamento. 2005 , 91, 36-48		

429	Biochronomer technology. 2005 , 2, 169-83	24
428	Anaemia of cancer: impact on patient fatigue and long-term outcome. 2005 , 69 Suppl 2, 2-7	66
427	A Receptor-Based Paradigm of Nausea and Vomiting. 2005 , 1, 11-23	4
426	Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics. 2005 , 9, 77-84	9
425	Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. 2005 , 39, 77-85	51
424	Clinical practice guidelines on antiemetics in oncology. 2005 , 5, 963-72	10
423	Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting. 2005 , 39, 1903-10	3
422	Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. 2005 , 6, 93-102	140
421	Antiemetic therapy in cancer: an update. 2005 , 6, 1713-23	
420	Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey. 2005 , 58, 291-303	21
419	The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. 2005 , 59, 60-70	236
418	Nausea: the neglected symptom?. 2005 , 9, 21-32	77
417	Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. 2005 , 2, 196-201	37
416	Breast Cancer and Molecular Medicine. 2006 ,	2
415	Assessing anaemia and fatigue: putting theory into practice. 2006 , 22, S1-S4	1
414	Advances in oral therapy for multiple myeloma. 2006 , 7, 316-25	34
413	Palliative care: a promising philosophical framework for gastroenterology. 2006 , 35, 1-21, vii	3
412	[Prevention and control of chemotherapy-induced nausea and vomiting]. 2006 , 126, 143-51	6

411	Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. 2006 , 3, 140-2	18
410	Symptom experiences during chemotherapy treatment--with focus on nausea and vomiting. 2006 , 10, 21-9	55
409	The potential for neuropsychology to inform functional outcomes research with breast cancer survivors. 2006 , 21, 51-64	14
408	Update on the management of chemotherapy-induced nausea and vomiting. 2006 , 29, 283-92	2
407	A qualitative study of factors affecting chemotherapy use in older women with breast cancer: barriers, promoters, and implications for intervention. 2006 , 15, 1065-76	66
406	Gastrointestinal toxicity of chemotherapeutic agents. 2006 , 33, 106-20	64
405	Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. 2006 , 26, 1221-31	74
404	Management of chemotherapy-induced nausea and vomiting. 2006 , 67, 410-3	0
403	Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?. 2007 , 13, 69-75	19
402	Body image dissatisfaction in cancer survivors. 2007 , 34, E36-41	45
401	[Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin]. 2007 , 127, 353-7	4
400	Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. 2007 , 43, 299-307	38
399	After going through chemotherapy I can't see another needle. 2007 , 11, 43-8	30
398	Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults. 2007 ,	2
397	Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. 2007 , 10, 23-31	36
396	Management of radiation-induced nausea and vomiting. 2007 , 35, 34-6	20
395	Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. 2007 , 34, 148-59	102
394	Akute Therapienebenwirkungen in der gynkologischen Onkologie. 2007 , 40, 852-860	

393	Cognitive function after chemotherapy in adults with solid tumours. 2007 , 63, 183-202		158
392	Minimising treatment-associated risks in systemic cancer therapy. 2008 , 30, 161-8		28
391	Preparing patients for threatening medical treatments: effects of a chemotherapy educational DVD on anxiety, unmet needs, and self-efficacy. <i>Supportive Care in Cancer</i> , 2008 , 16, 37-45	3.9	57
390	Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. <i>Supportive Care in Cancer</i> , 2008 , 16, 905-15	3.9	32
389	A review of patient self-report tools for chemotherapy-induced nausea and vomiting. <i>Supportive Care in Cancer</i> , 2008 , 16, 1213-29	3.9	34
388	Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. 2008 , 17, 317-28		269
387	Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia. 2008 , 17, 577-83		99
386	Antiemetics: an update and the MASCC guidelines applied in clinical practice. 2008 , 5, 32-43		78
385	Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. 2008 , 9, 3261-70		9
384	Assessing severity of epilepsy in children: preliminary evidence of validity and reliability of a single-item scale. 2008 , 13, 337-42		53
383	Análisis de coste-efectividad de granisetron en el tratamiento antiemético en oncología. 2008 , 5, 49-59		
382	Caring for the treatment-experienced breast cancer patient: the pharmacist's role. 2008 , 65, S16-22		9
381	Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. <i>Therapeutics and Clinical Risk Management</i> , 2009 , 5, 375-84	2.9	9
380	Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. 2009 , 43, 444-52		47
379	"The healthy me appears": palliative cancer patients' experiences of participation in a physical group exercise program. 2009 , 7, 459-67		28
378	The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. 2009 , 91, 367-73		13
377	Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial. 2009 , 14, 337-43		6
376	Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists. 2009 , 14, 518-24		11

375	Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. <i>Supportive Care in Cancer</i> , 2009 , 17, 181-9	3.9	48
374	Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. <i>Supportive Care in Cancer</i> , 2009 , 17, 563-72	3.9	117
373	Stability of an extemporaneous oral liquid aprepitant formulation. <i>Supportive Care in Cancer</i> , 2009 , 17, 701-6	3.9	17
372	A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. 2009 , 113, 529-35		65
371	Impact of alopecia and scalp cooling on the well-being of breast cancer patients. 2010 , 19, 701-9		56
370	Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients. 2009 , 71, 214-21		27
369	In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. 2009 , 3, 3707-13		656
368	Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. 2009 , 35, 289-96		15
367	Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting. 2009 , 6, 62-67		8
366	Perceptions of food and eating among Chinese patients with cancer: findings of an ethnographic study. 2009 , 32, 118-26		23
365	Application of an indwelling vascular access port for intravenous administration in a repeated and intermittent dose toxicity study in rats. 2009 , 34, 39-52		3
364	Complications digestives des chimiothérapies. 2010 , 5, 1-15		
363	Symptom assessment in children receiving cancer therapy: the parents' perspective. <i>Supportive Care in Cancer</i> , 2010 , 18, 281-99	3.9	67
362	Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting. <i>Supportive Care in Cancer</i> , 2010 , 18 Suppl 1, S1-10	3.9	49
361	Health-related quality of life in lung cancer patients in Serbia: correlation with socio-economic and clinical parameters. 2010 , 19, 594-602		8
360	Aprepitant: drug-drug interactions in perspective. 2010 , 21, 2316-2323		89
359	Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice. 2010 , 16, 233-44		15
358	Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. 2010 , 10, 137-48		12

357	Management of chemotherapy-induced nausea and vomiting. 2010 , 65, 305-10		5
356	Cytotoxicity of berberine on human cervical carcinoma HeLa cells through mitochondria, death receptor and MAPK pathways, and in-silico drug-target prediction. 2010 , 24, 1482-90		46
355	Chemotherapy, Cancer, and the Quality of Life: An Occupational Therapy Approach. 2010 , 34, 105-113		9
354	DNA binding to an anticancer organo-ruthenium complex. 2010 , 114, 14041-7		35
353	Quinoxalin-2-carboxamides: synthesis and pharmacological evaluation as serotonin type-3 (5-HT ₃) receptor antagonists. 2011 , 26, 610-5		11
352	Complementary therapies for side effects of chemotherapy and radiotherapy in the upper gastrointestinal system. 2011 , 3, 11-16		6
351	Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. 2011 , 10, 449-62		11
350	Treatment of chemotherapy-induced alopecia. 2011 , 24, 432-42		54
349	Implementation of best practice for chemotherapy-induced nausea and vomiting in an acute care setting. 2011 , 9, 32-8		13
348	Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. <i>Supportive Care in Cancer</i> , 2011 , 19, 1549-63	3.9	53
347	Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. <i>Supportive Care in Cancer</i> , 2011 , 19, 1983-90	3.9	36
346	Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. 2011 , 67, 783-90		4
345	Acceptance of oral chemotherapy in breast cancer patients - a survey study. 2011 , 11, 129		28
344	A qualitative exploration of Malaysian cancer patients' perspectives on cancer and its treatment. 2011 , 11, 525		32
343	Mitochondria-targeting single-walled carbon nanotubes for cancer photothermal therapy. 2011 , 7, 2727-35		129
342	The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. 2011 , 46, 784-9		23
341	Effectively managing chemotherapy-induced nausea and vomiting. 2011 , 20, S7-8, S10-2, S14-15		9
340	CINV in the UK: a prospective audit of patient experience. 2011 , 20, S29-31		1

339	A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. <i>Oncologist</i> , 2011 , 16, 207-16	5-7	43
338	Prophylaxis and treatment of chemotherapy-induced nausea and vomiting. 2011 , 16-23		
337	Medicinal plants as antiemetics in the treatment of cancer: a review. 2012 , 11, 18-28		24
336	Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial. 2012 , 23, 222-231		65
335	Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. 2012 , 104, 1280-92		93
334	Patient-centered management of chemotherapy-induced nausea and vomiting. 2012 , 19, 10-5		10
333	Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting. 2012 , 12, 139-50		10
332	Nontoxic concentrations of PEGylated graphene nanoribbons for selective cancer cell imaging and photothermal therapy. 2012 , 22, 20626		176
331	A systematic review of symptom assessment scales in children with cancer. 2012 , 12, 430		47
330	Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. 2012 , 83, 135-40		1
329	The effectiveness of fermented wheat germ extract as an adjunct therapy in the treatment of cancer: A systematic review. 2012 , 10, 1-12		2
328	Cancer Treatment Survey (CaTS): development and validation of a new instrument to measure patients' preparation for chemotherapy and radiotherapy. 2012 , 21, 307-15		19
327	Identifying psychological morbidity among people with cancer using the Hospital Anxiety and Depression Scale: time to revisit first principles?. 2012 , 21, 229-38		44
326	The use of a glucose-reduced graphene oxide suspension for photothermal cancer therapy. 2012 , 22, 13773		353
325	Ligand-based design, synthesis, and pharmacological evaluation of 3-Methoxyquinoxalin-2-carboxamides as structurally novel serotonin type-3 receptor antagonists. 2012 , 345, 687-94		9
324	Concepts of plant health ¶reviewing and challenging the foundations of plant protection. 2012 , 61, 1-15		40
323	Predictors of response to palliative care intervention for chronic nausea in advanced cancer outpatients. <i>Supportive Care in Cancer</i> , 2013 , 21, 2427-35	3-9	9
322	Bone Metastases. 2013 , 289-301		

321	Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review. 2013 , 11, 619-37	6
320	Preference weights for chemotherapy side effects from the perspective of women with breast cancer. 2013 , 142, 101-7	56
319	Facile synthesis of water-dispersible Cu ₂ O nanocrystal-reduced graphene oxide hybrid as a promising cancer therapeutic agent. 2013 , 5, 1227-32	48
318	Apigenin shows synergistic anticancer activity with curcumin by binding at different sites of tubulin. 2013 , 95, 1297-309	65
317	Graphene oxide modified PLA microcapsules containing gold nanoparticles for ultrasonic/CT bimodal imaging guided photothermal tumor therapy. 2013 , 34, 4794-802	165
316	[Reflections about the efficiency criteria for cancer treatments during marketing authorization application]. 2013 , 100, 259-69	2
315	FEATURES. 2013 , 17, 27-45	1
314	Palonosetron for the prevention of chemotherapy-induced nausea and vomiting. 2013 , 13, 919-36	3
313	Feasibility and acceptance of a pharmacist-run tele-oncology service for chemotherapy-induced nausea and vomiting in ambulatory cancer patients. 2013 , 19, 387-95	19
312	Quantitative assessment of appearance changes and related distress in cancer patients. 2013 , 22, 2140-7	39
311	Baseline blood work before initiation of chemotherapy: what is safe in the real world?. 2013 , 9, e182-5	5
310	[The importance of individual beliefs about cancer treatments for therapeutic decisions]. 2013 , 100, 999-1005	3
309	Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. 2013 , 24, 99-111	13
308	Chemotherapy-induced complications in patients with lung cancer: An evaluation by pharmacists. 2013 , 1, 65-68	7
307	Supportive and Palliative Care in Solid Cancer Patients. 2013 ,	1
306	Cancer (Vol. 17, No. 9, Full Issue). 2013 , 17,	
305	Refinement of the symptom screening in pediatrics tool (SSPedi). 2014 , 111, 1262-8	40
304	Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 2014 , 13, 139-50	20

303	Nanotechnology in Cancer Drug Delivery and Selective Targeting. 2014 , 2014, 1-12		163
302	Body image struggles and breast cancer care: an under-recognized and undertreated issue with important implications for all patients. 2014 , 3, 251-260		4
301	Patient preferences for side effects associated with cervical cancer treatment. 2014 , 24, 1077-84		8
300	Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study. 2014 , 170, 643-50		18
299	Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. 2014 , 25, 346-51		21
298	Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells. 2014 , 8, 12151-66		143
297	Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations. 2014 , 10, 168-73		20
296	Intra-individual variability in women with breast cancer. 2014 , 20, 380-90		24
295	Cognitive dysfunction after chemotherapy for breast cancer. 2014 , 20, 351-6		21
294	Effect on symptom control of structured information given to patients receiving chemotherapy. 2014 , 18, 78-84		20
293	Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. 2014 , 28, 1668-73		30
292	Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2014 , 22, 1199-206	3.9	8
291	Initial development of the Symptom Screening in Pediatrics Tool (SSPedi). <i>Supportive Care in Cancer</i> , 2014 , 22, 71-5	3.9	43
290	Investigating physical symptom burden and personal goal interference in early-stage breast cancer patients. <i>Supportive Care in Cancer</i> , 2014 , 22, 713-20	3.9	22
289	Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin. 2014 , 289, 859-64		13
288	Smart pH-responsive nanocarriers based on nano-graphene oxide for combined chemo- and photothermal therapy overcoming drug resistance. 2014 , 3, 1261-71		132
287	A qualitative study investigating chemotherapy-induced nausea as a symptom cluster. <i>Supportive Care in Cancer</i> , 2014 , 22, 2749-56	3.9	27
286	Supportive cryotherapy: a review from head to toe. 2014 , 47, 1100-15		28

285	Toward understanding the selective anticancer capacity of cold atmospheric plasma--a model based on aquaporins (Review). 2015 , 10, 040801			121
284	Examining the effects of adjuvant chemotherapy on cognition and the impact of any cognitive impairment on quality of life in colorectal cancer patients: study protocol. 2015 , 3, 43			4
283	Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review. 2015 , 24, 605-17			27
282	A review of symptom screening tools in pediatric cancer patients. 2015 , 27, 285-90			15
281	Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer. 2015 , 26, 547-54			26
280	Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool. <i>Supportive Care in Cancer</i> , 2015 , 23, 3331-9	3.9		3
279	Defining novel health-related quality of life domains in lung transplantation: a qualitative analysis. 2015 , 24, 1521-33			18
278	Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy. 2015 , 117, 333-7			16
277	Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study. 2015 , 32, 240			8
276	A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents. [Corrected]. 2015 , 6, 10081			87
275	Can administrative data be used to measure chemotherapy side effects?. 2015 , 15, 215-22			3
274	Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. <i>Supportive Care in Cancer</i> , 2015 , 23, 2833-40	3.9		40
273	Core-shell-shell nanorods for controlled release of silver that can serve as a nanoheater for photothermal treatment on bacteria. 2015 , 11, 511-9			53
272	Taurine attenuates chemotherapy-induced nausea and vomiting in acute lymphoblastic leukemia. 2015 , 47, 101-9			13
271	Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities. 2015 , 89, 540-8			24
270	Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents. 2016 , 13,			61
269	Polydopamine Nanoparticles as a Versatile Molecular Loading Platform to Enable Imaging-guided Cancer Combination Therapy. 2016 , 6, 1031-42			196
268	Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting. 2016 , 36, 218-29			10

267	Preferences of lung cancer patients for treatment and decision-making: a systematic literature review. 2016 , 25, 580-91		29
266	Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: What about the guidelines?. 2016 , 4, 46-51		7
265	Action of newly developed tetrazolato-bridged dinuclear platinum(II) complexes as the candidate of effective antitumor drug on the structure of large DNA. 2016 ,		
264	Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?. 2016 , 78, 673-83		44
263	biomechanical properties, fluorescence imaging, surface-enhanced Raman spectroscopy, and photothermal therapy evaluation of luminescent functionalized CaMoO:Eu@Au hybrid nanorods on human lung adenocarcinoma epithelial cells. 2016 , 17, 346-360		17
262	Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology. 2016 , 5, 3128-3139		38
261	Crystal structures of organoplatinum complexes containing alkyl-eugenoxycetate and p-chloro-aniline. 2016 , 72, 912-7		1
260	Role of Biomarkers in the Development of PARP Inhibitors. 2016 , 8, 15-25		53
259	Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. <i>Supportive Care in Cancer</i> , 2016 , 24, 4559-66	3.9	3
258	New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting. 2016 , 17, 1623-9		1
257	Simulation of scalp cooling by external devices for prevention of chemotherapy-induced alopecia. 2016 , 56, 31-8		2
256	A study of the potential anticancer activity of bark: Evaluation of cytotoxic and apoptotic effects of the hexane extract and bioassay-guided fractionation to identify phytochemical constituents. 2016 , 11, 1335-1344		28
255	Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy. 2016 , 46, 415-20		2
254	Nanoparticle systems reduce systemic toxicity in cancer treatment. 2016 , 11, 103-6		52
253	Controlled release tablet formulation containing natural (D)-tetrahydrocannabinol. 2016 , 42, 1158-64		3
252	Parent Attributions About Child Symptoms Related to Cancer Therapy. 2017 , 34, 44-50		6
251	Integrative Therapeutic Approaches for the Management and Control of Nausea in Children Undergoing Cancer Treatment: A Systematic Review of Literature. 2017 , 34, 173-184		15
250	A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. <i>Supportive Care in Cancer</i> , 2017 , 25, 2505-2513	3.9	4

249	Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. 2017 , 22, 405-412		17
248	Dual-stimuli responsive and reversibly activatable theranostic nanoprobe for precision tumor-targeting and fluorescence-guided photothermal therapy. 2017 , 8, 14998		158
247	Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation. 2017 , 57, 1400-1408		2
246	Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view. 2017 , 134, 159-184		273
245	Facile synthesis and antiproliferative activity of 7H-benzo[7,8]chromeno[2,3-d]pyrimidin-8-amines. 2017 , 127, 128-136		10
244	Enhancing the photothermal stability and photothermal efficacy of AuNRs and AuNTs by grafting with Ru(II) complexes. 2017 , 5, 671-678		12
243	Text Messaging (SMS) Helping Cancer Care in Patients Undergoing Chemotherapy Treatment: a Pilot Study. 2017 , 41, 181		16
242	Computational Approaches to Identify Genetic Interactions for Cancer Therapeutics. 2017 , 14,		2
241	TiO ₂ Based Nanoplatform for Bimodal Cancer Imaging and NIR-Triggered Chem/Photodynamic/Photothermal Combination Therapy. 2017 , 29, 9262-9274		92
240	Near-infrared light-mediated LA-UCNPs@SiO ₂ -C/HA@mSiO ₂ -DOX@NB nanocomposite for chemotherapy/PDT/PTT and imaging. 2017 , 46, 14293-14300		19
239	NIR light-triggered shrinkable thermoresponsive PNVCL nanoshells for cancer theranostics. 2017 , 7, 44026-44034		16
238	Doxorubicin and Indocyanine Green Loaded Hybrid Bicelles for Fluorescence Imaging Guided Synergetic Chemo/Photothermal Therapy. 2017 , 28, 2410-2419		32
237	The Modeling of Temperature Distributions of an Interstitial Two-Tine Antenna for Hepatic cancer Microwave Ablation. 2017 ,		
236	Patient perceptions of symptoms and concerns during cancer chemotherapy: 'affects my family' is the most important. 2017 , 22, 793-800		16
235	In vitro and in vivo evaluation of paclitaxel-lapatinib-loaded F127 pluronic micelles. 2017 , 43, 390-398		13
234	Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. <i>Supportive Care in Cancer</i> , 2017 , 25, 801-809	3.9	7
233	Modulating Drug Release Rate from Partially Silica-Coated Bicellar Nanodisc by Incorporating PEGylated Phospholipid. 2017 , 28, 53-63		18
232	Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. <i>Supportive Care in Cancer</i> , 2017 , 25, 145-154	3.9	21

231	Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2017 , 25, 85-92	3.9	9
230	Dual-pH Sensitive Charge-reversal Nanocomplex for Tumor-targeted Drug Delivery with Enhanced Anticancer Activity. 2017 , 7, 1806-1819		54
229	Magnetic nanoparticles and cancer. 2017 , 105-137		4
228	Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. 2017 , 12, e0184360		189
227	Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV). 2017 , 11, 947-954		3
226	Mn-coordinated PDA@DOX/PLGA nanoparticles as a smart theranostic agent for synergistic chemo-photothermal tumor therapy. 2017 , 12, 3331-3345		60
225	Novel herbal medicine LA16001 ameliorates cisplatin-induced anorexia. 2018 , 17, 2665-2672		3
224	Experimental study of the anti-tumour activity and pharmacokinetics of arctigenin and its valine ester derivative. 2018 , 8, 3307		6
223	Folic-Acid-Functionalized Graphene Oxide Nanocarrier: Synthetic Approaches, Characterization, Drug Delivery Study, and Antitumor Screening. <i>ACS Applied Nano Materials</i> , 2018 , 1, 922-932	5.6	59
222	Dual-Targeted Selenium Nanoparticles for Synergistic Photothermal Therapy and Chemotherapy of Tumors. 2018 , 13, 996-1004		30
221	Effects of doxorubicin on the structural and morphological characterization of solid lipid nanoparticles (SLN) using small angle neutron scattering (SANS) and small angle X-ray scattering (SAXS). 2018 , 551, 191-196		5
220	Toxic Reactive Oxygen Species Enhanced Synergistic Combination Therapy by Self-Assembled Metal-Phenolic Network Nanoparticles. 2018 , 30, 1704877		211
219	[Chemotherapy-induced nausea and vomiting : Current recommendations for prophylaxis]. 2018 , 57, 532-542		2
218	Chemotherapeutic agents induce mitochondrial superoxide production and toxicity but do not alter respiration in skeletal muscle in vitro. 2018 , 42, 33-49		9
217	Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy. <i>Supportive Care in Cancer</i> , 2018 , 26, 483-489	3.9	8
216	Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al. 2018 , 27, 149-152		3
215	Recent advances in metal nanoparticles in cancer therapy. 2018 , 26, 617-632		153
214	Awakening p53 by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery. 2018 , 8, 5320-5335		22

213	Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective. 2018 , 9, 1442		20
212	Application of polydopamine in tumor targeted drug delivery system and its drug release behavior. 2018 , 290, 56-74		93
211	Peptide-Induced Self-Assembly of Therapeutics into a Well-Defined Nanoshell with Tumor-Triggered Shape and Charge Switch. 2018 , 30, 7034-7046		23
210	Nausea and Vomiting. 2018 , 391-408		
209	MicroRNA-299-3p regulates proliferation, migration and invasion of human ovarian cancer cells by modulating the expression of OCT4. 2018 , 651, 21-27		15
208	In situ fluorescence monitoring of diagnosis and treatment: a versatile nanoprobe combining tumor targeting based on MUC1 and controllable DOX release by telomerase. 2018 , 54, 8277-8280		22
207	Indoles: As Multitarget Directed Ligands in Medicinal Chemistry. 2018 , 285-321		6
206	Natural Products for the Management and Prevention of Breast Cancer. 2018 , 2018, 8324696		81
205	Recent advances in antiemetics: new formulations of 5HT-receptor antagonists. <i>Cancer Management and Research</i> , 2018 , 10, 1827-1857	3.6	19
204	AMPH-1 is critical for breast cancer progression. 2018 , 9, 2175-2182		6
203	The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia. 2018 , 14, 2461-2469		6
202	Novel natural compounds from endophytic fungi with anticancer activity. 2018 , 156, 316-343		44
201	Tumor targeting via EPR: Strategies to enhance patient responses. 2018 , 130, 17-38		618
200	BODIPY-based Ir(III) rectangles containing bis-benzimidazole ligands with highly selective toxicity obtained through self-assembly. 2018 , 868, 86-94		13
199	Preparation and photothermal therapy of hyaluronic acid-conjugated Au nanoparticle-coated poly (glycidyl methacrylate) nanocomposites. 2018 , 53, 16252-16262		5
198	Anti-Cancer Natural Products and Their Bioactive Compounds Inducing ER Stress-Mediated Apoptosis: A Review. 2018 , 10,		154
197	Biofunctionalized Mesoporous Silica Nanomaterials for Targeted Drug Delivery. 2018 , 489-520		3
196	Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. 2018 , 171, 627-634		16

195	One-pot synthesis of hollow PDA@DOX nanoparticles for ultrasound imaging and chemo-thermal therapy in breast cancer. 2019 , 11, 21759-21766	32
194	Impact of ROS Generated by Chemical, Physical, and Plasma Techniques on Cancer Attenuation. 2019 , 11,	67
193	Optimizing symptom control in children and adolescents with cancer. 2019 , 86, 573-578	17
192	A Novel Drug Design Strategy: An Inspiration from Encaging Tumor by Metallofullerenol Gd@C(OH). 2019 , 24,	3
191	Drug Management Pattern and Their Adverse Effects in Patients of Cervical Carcinoma Attending Two Tertiary Care Hospitals in Dhaka City. 2019 , 9, 104-109	1
190	Folic acid and rhodamine labelled pH responsive hyperbranched polymers: Synthesis, characterization and cell uptake studies. 2019 , 120, 109259	8
189	A New Coordination Polymer for Effective 5-fluorouracil Loading and Anti-lung Cancer Activity Study. 2019 , 45, 817-823	
188	CYTOTOXIC EFFECTS OF ARIPIRAZOLE ON MKN45 AND NIH3T3 CELL LINES AND GENOTOXIC EFFECTS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES. <i>Arquivos De Gastroenterologia</i> , 2019 , 56, 155-139	6
187	Identification of chemical changes in healthy breast tissue caused by chemotherapy using Raman and FTIR spectroscopy: A preliminary study. 2019 , 102, 102989	10
186	Effect of Ultrasound on the Vasculature and Extravasation of Nanoscale Particles Imaged in Real Time. 2019 , 45, 3028-3041	14
185	Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor. 2019 , 12, 357-373	8
184	Acupuncture in Oncology. 2019 , 373-405	
183	Redox-Responsive and Dual-Targeting Hyaluronic Acid-Methotrexate Prodrug Self-Assembling Nanoparticles for Enhancing Intracellular Drug Self-Delivery. 2019 , 16, 3133-3144	13
182	Comprehensive Evaluation of Degradable and Cost-Effective Plasmonic Nanoshells for Localized Photothermolysis of Cancer Cells. 2019 , 35, 7805-7815	11
181	PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution. 2019 , 9, 721-734	66
180	Polydopamine-modified ROS-responsive prodrug nanoplatform with enhanced stability for precise treatment of breast cancer.. 2019 , 9, 9260-9269	9
179	Factors associated with receipt of symptom screening in the year after cancer diagnosis in a universal health care system: a retrospective cohort study. 2019 , 26, e8-e16	6
178	Bombesin conjugated solid lipid nanoparticles for improved delivery of epigallocatechin gallate for breast cancer treatment. 2019 , 224, 104770	29

177	Phytochemical Modulation of MiRNAs in Colorectal Cancer. 2019 , 6,		2
176	Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. 2019 , 23, 447-456		5
175	Flower-like FeS/BiS superstructures with improved near-infrared absorption for efficient chemo-photothermal therapy. 2019 , 48, 3360-3368		9
174	Graphene nano-ribbon based high potential and efficiency for DNA, cancer therapy and drug delivery applications. 2019 , 51, 91-104		31
173	Potential physical and biological barriers leading to failure of cancer chemotherapy. 2019 , 1-21		1
172	Nanotechnological strategies involved in the targeted delivery of anticancer drugs. 2019 , 23-41		
171	Metal-Phenolic Network-Based Nanocomplexes that Evoke Ferroptosis by Apoptosis: Promoted Nuclear Drug Influx and Reversed Drug Resistance of Cancer. 2019 , 31, 10071-10084		53
170	Synthesis, Crystal Structures of Two Novel Metal Coordination Polymers and Study of Their Inhibition of Human Hemangioma Cells. 2019 , 60, 1850-1856		2
169	A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. 2019 , 14, e0208118		10
168	Fabrication of polydopamine-based layer-by-layer nanocomposites for combined pH-sensitive chemotherapy and photothermal therapy. 2019 , 561, 332-340		32
167	Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. <i>Oncologist</i> , 2019 , 24, e347-e357	5-7	15
166	ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. <i>Supportive Care in Cancer</i> , 2019 , 27, 87-95 ³⁻⁹		42
165	Patient-reported outcomes of the relative severity of side effects from cancer radiotherapy. <i>Supportive Care in Cancer</i> , 2020 , 28, 309-316	3-9	5
164	Nausea and Vomiting. 2020 , 598-606.e3		
163	Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial. <i>Supportive Care in Cancer</i> , 2020 , 28, 3605-3615	3-9	5
162	Exploratory Factor Analysis of a Patient-Centered Cancer Care Measure to Support Improved Assessment of Patients' Experiences. 2020 , 23, 351-361		3
161	Evaluation of efficacy of QR678 and QR678 Neo hair growth factor formulation in the treatment of persistent chemotherapy-induced alopecia caused due to cytotoxic chemotherapy-A prospective pilot study. 2020 , 19, 3270-3279		2
160	Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions. 2020 , 156, 103093		3

159	A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting. 2020 , 109, 101925	1
158	Influence of Riboflavin Targeting on Tumor Accumulation and Internalization of Peptostar Based Drug Delivery Systems. 2020 , 31, 2691-2696	4
157	Combined ligand and structure-based virtual screening approaches for identification of novel AChE inhibitors. 2020 , 44, 574-588	1
156	Resistance Exercise and Art Therapy on Body Image in Breast Cancer: A Scoping Review. 2020 , 1, 424-435	1
155	A minireview on multiparameter-activated nanodevices for cancer imaging and therapy. 2020 , 12, 21571-21582	2
154	Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. 2020 , 16, 2959-2979	12
153	Advancing Therapies for Cancer From Mustard Gas to CAR T. 2020 , 2, 90	1
152	Preparation and Evaluation of Rebamipide Colloidal Nanoparticles Obtained by Cogrinding in Ternary Ground Mixtures. 2020 , 4, 43	0
151	Advancing Therapies for Cancer From Mustard Gas to CAR T. 2020 , 2, 70	1
150	Rational design and latest advances of codelivery systems for cancer therapy. 2020 , 7, 100056	22
149	Co-delivery of doxorubicin and DNAzyme using ZnO@polydopamine core-shell nanocomposites for chemo/gene/photothermal therapy. 2020 , 110, 242-253	23
148	TAT-modified redox-sensitive nanoparticles for triggered drug delivery and effective breast cancer therapy. 2020 , 57, 101709	3
147	Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting. 2020 , 11, 4560-4570	2
146	Palliative Gastroenterology. 2020 , 1-12	1
145	Cantharidin-loaded functional mesoporous titanium peroxide nanoparticles for non-small cell lung cancer targeted chemotherapy combined with high effective photodynamic therapy. 2020 , 11, 1476-1486	11
144	A competent bidrug loaded water soluble chitosan derivative for the effective inhibition of breast cancer. 2020 , 10, 3991	12
143	Advancing Therapies for Cancer From Mustard Gas to CAR T. 2020 , 2, 42	1
142	Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals. 2020 , 25,	9

141	Recent advances in dendrimer-based nanoplatform for cancer treatment: A review. 2020 , 126, 109546		48
140	Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective. 2020 , 10, 400		3
139	Progressive muscle relaxation is effective in preventing and alleviating of chemotherapy-induced nausea and vomiting among cancer patients: a systematic review of six randomized controlled trials. <i>Supportive Care in Cancer</i> , 2020 , 28, 4051-4058	3.9	5
138	Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells. 2021 , 199, 1316-1331		22
137	Effect of Acoustic Radiation Force on the Distribution of Nanoparticles in Solid Tumors. 2021 , 68, 432-445		5
136	Acoustically Mediated Controlled Drug Release and Targeted Therapy with Degradable 3D Porous Magnetic Microrobots. 2021 , 10, e2001096		30
135	Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies. 2021 ,		
134	Role of targeted drug delivery in cancer therapeutics. 2021 , 327-354		0
133	A Smartphone-Based Decision Support Tool for Predicting Patients at Risk of Chemotherapy-Induced Nausea and Vomiting: Retrospective Study on App Development Using Decision Tree Induction. 2021 , 9, e27024		0
132	Polymeric nanomaterials in neuroscience. 2021 , 291-307		
131	Effectiveness of Self-care Measures on Knowledge, Self-efficacy and Performance Status among Cancer Patients. 2021 , 10, 1-8		0
130	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. 2021 , 10,		2
129	Translation of the Pediatric Nausea Assessment Tool (PeNAT) Into Spanish and Evaluating Understandability Among Spanish-Speaking Hispanic American Children and Adolescents Receiving Chemotherapy. 2021 , 15404153211003341		0
128	Design, Synthesis and Biological Evaluation of Novel 5-Phenyl-5-(thiophen-2-yl)-4H-1,2,4-triazole-3-thiols as an Anticancer Agent. 2021 , 6, 3240-3255		
127	A qualitative evaluation of community and acute hospital nursing oncology services in Ireland. 2021 , 51, 101912		1
126	Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. 2021 , 28, 935-946		5
125	Mesoporous organosilica nanoparticles: Degradation strategies and application in tumor therapy. 2021 , 2, 20200117		6
124	Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database. 2021 , e1482		2

123	Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance. 2021 , 46, 1404-1411		1
122	On the selective killing of cold atmospheric plasma cancer treatment: Status and beyond. 2021 , 18, 2100020		2
121	Survey of chemotherapy-induced nausea and vomiting in patients with urothelial carcinoma. 2021 , 15, 219		
120	Chemical constituents from basidiomycete <i>Basidioradulum radula</i> culture medium and their cytotoxic effect on human prostate cancer DU-145 cells. 2021 , 114, 105064		
119	Computational Screening of Natural Compounds for Identification of Potential Anti-Cancer Agents Targeting MCM7 Protein. 2021 , 26,		7
118	Mesoporous silica nanoparticles with fluorescent and magnetic dual-imaging properties to deliver fucoidan. 2021 , 188, 870-878		2
117	Palliative Gastroenterology. 2021 , 2047-2058		
116	Patient's Perspective. 281-296		3
115	Psychosocial aspects of patients with lung cancer in controlled clinical trials. <i>Cancer Treatment and Research</i> , 1989 , 45, 325-55	3.5	2
114	Cannabinoids and the Control of Chemotherapy-Induced Nausea and Vomiting. 1999 , 599-610		3
113	Quality of Life Assessment in Cancer Clinical Trials. 1990 , 97-113		5
112	Symptom Control in Palliative Home Care. 1990 , 19-39		1
111	Economic Evaluation of Cancer Treatments. 1990 , 63-84		2
110	Ondansetron : Dose schedules and duration of treatment. 1991 , 53-64		1
109	Coping with Cytotoxic Therapy. 1986 , 39-44		2
108	Electrospun nanofibers: a promising horizon toward the detection and treatment of cancer. 2020 , 145, 2854-2872		14
107	Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. 1999 , 22, 94-6		28
106	Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. 1999 , 22, 126-30		4

105	Relaxation to reduce nausea, vomiting, and anxiety induced by chemotherapy in Japanese patients. 1997 , 20, 342-9		74
104	The distress associated with cranial irradiation: a comparison of patient and nurse perceptions. 1999 , 22, 126-33		6
103	Quality of Life Assessment in Palliative Care. 1992 , 8, 34-39		10
102	Ferruginol Diterpenoid Selectively Inhibits Human Thyroid Cancer Growth by Inducing Mitochondrial Dependent Apoptosis, Endogenous Reactive Oxygen Species (ROS) Production, Mitochondrial Membrane Potential Loss and Suppression of Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway. 2019 , 25, 5054-5061		11
101	Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. 2019 , 25, 5054-5061		6
100	Factors Associated with Metastatic Breast Cancer in Patients Who Show Long-Term Stable Disease Status. 2017 , 5, 1-7		2
99	Tool Development to Assess Nausea and Vomiting Among Patients Receiving Chemotherapy. 2016 , 3, 1-5		2
98	[Prophylaxis of chemotherapy-induced vomiting and nausea]. 2008 , 52, 391-4		2
97	[Treatment of tumor therapy-induced nausea and vomiting]. 2009 , 53, 39-45		0
96	CYTOTOXIC EFFECTS OF DULOXETINE ON MKN45 AND NIH3T3 CELL LINES AND GENOTOXIC EFFECTS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES. <i>Arquivos De Gastroenterologia</i> , 2019 , 56, 372-376	1,3	8
95	An overview of the clinical use of ondansetron in preschool age children. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 333-9	2.9	12
94	Gold Nanoparticles- Boon in Cancer Theranostics. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5134-5151	3.3	4
93	New Perspectives in the Treatment of Tumor Cells by Electromagnetic Radiation at Resonance Frequencies in Cellular Membrane Channels. <i>Open Biotechnology Journal</i> , 2019 , 13, 105-110	2	1
92	Management of Nausea and Vomiting. 1999 , 232-247		1
91	Investigation into the Effect of Photodynamic Therapy and Cisplatin on the Cervical Cancer Cell Line (A2780). <i>Journal of Lasers in Medical Sciences</i> , 2020 , 11, S85-S91	1.6	2
90	Efficacy of Rasayana Avaleha as adjuvant to radiotherapy and chemotherapy in reducing adverse effects. <i>AYU: an International Quarterly Journal of Research in Ayurveda</i> , 2010 , 31, 417-23	0.3	27
89	Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients. <i>Cancer Research and Treatment</i> , 2004 , 36, 372-6	5.2	3
88	Antiemetic Guidelines: Not Just for the HEC of It. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 791-792	7.3	1

87	Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013 , 14, 5995-6000	1.7	11
86	Side effects of chemotherapy among cancer patients in a Malaysian General Hospital: experiences, perceptions and informational needs from clinical pharmacists. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 5305-9	1.7	47
85	Engineered Hyaluronic Acid-Based Smart Nanoconjugates for Enhanced Intracellular Drug Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2021 ,	3.9	1
84	Massage therapy for chemotherapy-induced emesis. 2002 , 85-104		
83	Supportivmaßnahmen in der Therapie gynäkologischer Malignome. 2002 , 136-145		
82	Supportive care. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003 , 21, 709-16		
81	Richtlinien zur antiemetischen Therapie. 2006 , 2132-2161		
80	Alopezie nach Chemotherapie. 2006 , 2244-2247		
79	Nausea/Vomiting, Anorexia/Cachexia, and Fatigue. 2007 , 115-132		
78	Survey of Serotonin Receptor Antagonist Usage at National Cancer Center Hospital. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2007 , 33, 424-430	0.1	
77	Nausea and Vomiting. 2008 , 599-608		
76	Nausea and Vomiting. 2009 , 179-192		
75	Nausea and Vomiting. 2010 , 231-239		
74	The Burden of Chemotherapy Induced Nausea and Vomiting on Patients' Daily Lives: Italian Perspectives. 2010 , 885-898		
73	Efficacy of Aprepitant for Nausea and Vomiting and Examination of Its Influence on Hiccups. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2011 , 37, 713-720	0.1	
72	Nausea and Vomiting in Cancer. 2012 , 107-130		
71	Evaluation of Antiemetics Chosen by Patients and Antiemetic Effects in EC Therapy for Breast Cancer. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2012 , 38, 584-591	0.1	
70	Dietary and Non-dietary Phytochemicals in Cancer Control. 2012 , 585-622		2

69	Introduction. 2013 , 1-3		
68	Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2013 , 39, 437-443	0.1	
67	Nausea and Vomiting. 2014 , 626-634.e2		0
66	Problematik randomisierter Studien zur Definition optimaler Therapien beim metastasierenden Mammakarzinom. 1986 , 71-83		
65	Current management and controversies. The patient's view. <i>Cancer Treatment and Research</i> , 1989 , 41, 167-85	3.5	
64	Measurement of Quality of Life in Cancer Research. 1989 , 458-466		
63	Control of cisplatin induced emesis--a multidisciplinary intervention strategy. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1992 , 9, 81-6		6
62	Clinical Effects of 5-HT ₃ Antagonists in Treating Nausea and Vomiting. <i>Medical Science Symposia Series</i> , 1993 , 187-196		
61	Granisetron, ein neues und potentes Antiemetikum zur Behandlung der zytostatikainduzierten Emesis. 1993 , 1068-1070		
60	Control of refractory nausea and vomiting with adjuvant propofol during cancer chemotherapy. 1994 , 705-706		
59	Antiemetic Therapy in Paediatric Patients. 1996 , 91-98		
58	Alternative Therapies in the Treatment of Chemotherapy-Induced Nausea and Vomiting. 1996 , 123-136		
57	Supportivtherapie. 1996 , 1047-1221		
56	Etiology and Prevention of Emesis Induced by Radiotherapy. 1998 , 95-111		
55	Recent Trend and Problems of Health Economics in Japan: Application of Clinical Economics to the Treatment for Cancers and Intractable Diseases. 1998 , 155-166		
54	A PROSPECTIVE OBSERVATIONAL STUDY TO COMPARE THE ANTIEMETIC EFFICACY AND SAFETY PROFILE OF TWO COMBINATIONS NAMELY ONDANSETRON-DEXAMETHASONE VERSUS PALONOSETRON-DEXAMETHASONE IN PROPHYLAXIS OF CISPLATIN INDUCED EMESIS. <i>Journal of Evaluation of Medical Devices</i> , 2011 , 5, 1211-1218	0.1	
53	The Impact on Quality of Life of Highly Effective Antiemetic Therapy among Breast Cancer Patients Receiving Anthracycline Plus Cyclophosphamide-based Regimen. <i>The Showa University Journal of Medical Sciences</i> , 2018 , 30, 285-296	0.1	
52	DeepACPred: A Novel Hybrid CNN-RNN Architecture for Predicting Anti-Cancer Peptides. <i>Advances in Intelligent Systems and Computing</i> , 2021 , 60-69	0.4	4

51	Dissecting Cellulitis of the Scalp: A Review and Case Studies of Surgical Reconstruction. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2020 , 8, e3015	1.2	3
50	Patients' Preferences: What Makes Treatments Worthwhile?. 2006 , 925-944		
49	Nanotheranostics. 2020 , 63-94		
48	Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. <i>Cmaj</i> , 1993 , 149, 296-302	3.5	24
47	Nausea and vomiting and cancer patients' quality of life: a discussion of Professor Selby's paper. <i>The British Journal of Cancer Supplement</i> , 1992 , 19, S26-9		7
46	The impact of nausea and vomiting upon quality of life measures. <i>The British Journal of Cancer Supplement</i> , 1992 , 19, S14-22; discussion S23		11
45	Palonosetron as an anti-emetic and anti-nausea agent in oncology. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 1009-20	2.9	35
44	Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron. <i>Cancer Management and Research</i> , 2009 , 1, 89-97	3.6	1
43	Understanding and improving platinum anticancer drugs--phenanthriplatin. <i>Anticancer Research</i> , 2014 , 34, 471-6	2.3	202
42	Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. <i>Annals of Gastroenterology</i> , 2012 , 25, 106-118	2.2	106
41	Chemotherapy-induced nausea and vomiting: optimizing prevention and management. <i>American Health and Drug Benefits</i> , 2012 , 5, 232-40	1.7	29
40	Management of Patients With Chemotherapy-Induced Nausea and Vomiting. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017 , 8, 303-308	0.7	1
39	A Smartphone-Based Decision Support Tool for Predicting Patients at Risk of Chemotherapy-Induced Nausea and Vomiting: Retrospective Study on App Development Using Decision Tree Induction (Preprint).		
38	Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. <i>International Journal of Colorectal Disease</i> , 2021 , 1	3	0
37	Prevalence of breakthrough chemotherapy-induced nausea vomiting in patients on highly emetogenic chemotherapy: A Single-center observational study. <i>Oncology Journal of India</i> , 2021 , 5, 92	0.2	
36	Co-delivery of Chemotherapeutic Drugs and Immune Adjuvants by Nanoscale DNA Tetrahedrons for Synergistic Cancer Therapy. <i>ACS Applied Nano Materials</i> , 2022 , 5, 101-106	5.6	3
35	Phosphatidylserine Exposed Lipid Bilayer Models for Understanding Cancer Cell Selectivity of Natural Compounds: A Molecular Dynamics Simulation Study.. <i>Membranes</i> , 2022 , 12,	3.8	1
34	On the receiving end: have patient perceptions of the side-effects of cancer chemotherapy changed since the twentieth century?. <i>Supportive Care in Cancer</i> , 2022 , 30, 3503	3.9	0

33	Synergistic effect of avidin/biotin system with biofunctionalized graphene oxide based nanocarrier in targeted co-delivery of hydrophobic anticancer drug SN -38. <i>Journal of Vinyl and Additive Technology</i> ,	2	1
32	Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study. <i>Oncologist</i> ,	5.7	0
31	Multifaceted Engineered Biomimetic Nanorobots Toward Cancer Management.. <i>ACS Biomaterials Science and Engineering</i> , 2022 ,	5.5	0
30	Using Natural Language Processing Techniques to Detect Adverse Events From Progress Notes Due to Chemotherapy.. <i>Cancer Informatics</i> , 2022 , 21, 11769351221085064	2.4	0
29	Certified nurse specialists in cancer nursing and prophylactic antiemetic prescription for chemotherapy patients.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	
28	Toward Incorporating Health-Related Quality of Life as Coprimary End Points in Clinical Trials: Time to Achieve Clinical Important Differences and QoL Profiles.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102750	7.5	1
27	Polydopamine surface-modified nanocarriers for improved anticancer activity: Current progress and future prospects. <i>OpenNano</i> , 2022 , 100059	8.4	2
26	A systematic review on potential anticancer activities of <i>Ficus carica</i> L. with focus on cellular and molecular mechanisms. <i>Phytomedicine</i> , 2022 , 154333	6.5	2
25	The chemotherapy-induced nausea and vomiting in children and adolescents receiving highly emetogenic chemotherapy. Hidden problem. 2022 , 9, 46-53		1
24	Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products. 2022 , 2022, 1-23		
23	Mesoporous Polydopamine-Based Nanovehicles as a Versatile Drug Loading Platform to Enable Tumor-Sufficient Synergistic Therapy.		
22	Advances in the Management of Nausea and Vomiting. 1990 , 25, 475-497		4
21	Potent Chlorambucil-Platinum(IV) Prodrugs. 2022 , 23, 10471		1
20	Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study. 2022 , 8,		0
19	Prevenç e tratamento das náuseas e vômitos induzidos pela quimioterapia antineoplásica. 2022 , 45, 31-39		0
18	The Use of Nanorobotics in the Treatment Therapy of Cancer and Its Future Aspects: A Review. 2022 ,		0
17	Rapamycin Liposomes Combined with 5-Fluorouracil Inhibits Angiogenesis and Tumor Growth of APC (Min/+) Mice and AOM/DSS-Induced Colorectal Cancer Mice. Volume 17, 5049-5061		0
16	Antiemetic Therapy. 1-9		0

- 15 The development of a novel antioxidant-based antiemetic drug to improve quality of life during anticancer therapy. **2022**, 32, 101363 ○
- 14 7-hydroxycoumarin modulates Nrf2/HO-1 and microRNA-34a/SIRT1 signaling and prevents cisplatin-induced oxidative stress, inflammation, and kidney injury in rats. **2022**, 310, 121104 ○
- 13 Effects of hirsuteine on MDA-MB-453 breast cancer cell proliferation. **2022**, 25, ○
- 12 Applications of Metallic Nanoparticles in the Skin Cancer Treatment. **2022**, 2022, 1-20 ○
- 11 ZIF-90 nanoparticles modified with a homing peptide for targeted delivery of cisplatin. 10, ○
- 10 Feasibility of three times weekly symptom screening in pediatric cancer patients. **2023**, 23, ○
- 9 Retrospective cohort study of scalp cooling in breast cancer patients. **2023**, 31, ○
- 8 A New Fuzzy Reinforcement Learning Method for Effective Chemotherapy. **2023**, 11, 477 ○
- 7 Nanorobots: An innovative approach for DNA-based cancer treatment. **2023**, 80, 104173 1
- 6 Development of Serotonin Antagonists for the Control of Chemotherapy-Induced Emesis. **1993**, 9, 279-284 1
- 5 Self-Compassion and Chronic Medical Conditions. **2023**, 329-346 ○
- 4 Catalytically Active Metal-Organic Frameworks Elicit Robust Immune Response to Combination Chemodynamic and Checkpoint Blockade Immunotherapy. **2023**, 15, 6442-6455 ○
- 3 Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer. **2023**, 11, 3453-3472 ○
- 2 Concept of body image and its mental health implications. **2022**, 18, 11 ○
- 1 Reactive oxygen species overload: a review of plasma therapy and photobiomodulation for cancer treatment. **2023**, 12, 18-28 ○